Homepage Top Section1

The therapy is indicated to improve functional capacity and symptoms. The regulatory decision was supported by findings from the double-blind, randomised Phase III SCOUT-HCM trial, which assessed the

The initiative is supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario. It is designed to help post-seed health science enterprises secure

The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan, whilst Tanabe Pharma retains marketing rights within Japan. The terms also include equity consideration and tiered royalties on

The preclinical T-cell engagers will be developed using Amberstone’s Tumor Microenvironment Activated ThErapeutics (T-MATE) platform. Henlius will select up to two targets under the agreement. The company will

The authorisation allows both treatments to be used for patients with primary hypercholesterolaemia, including those with heterozygous familial and non-familial forms or mixed dyslipidaemia. This is said to

The candidate is in early-stage development and references Hemlibra (emicizumab), a medicine used to treat patients with haemophilia A. The companies said the reference medicine has estimated global

The deal grants Ona Therapeutics rights to develop the ADC targeting a single undisclosed target. It includes an upfront payment from Ona Therapeutics to WuXi XDC, along with

The approval covers patients with OSAS who continue to experience EDS while receiving treatment for airway obstruction. It also applies to narcolepsy with and without cataplexy, a condition

Insight Partners and Medical Excellence Capital led the round, with additional investment from Pfizer Ventures and M Ventures, the corporate venture capital arm of Merck KGaA, all joining